PHARMACOLOGICAL CORRECTION OF SYMPATHETIC HYPERTONUS ASSOCIATED CALCIUM ANTAGONISTS PRESCRIBED IN PATIENTS WITH COMBINED ARTERIAL HYPERTENSION AND BRONCHIAL ASTHMA Russian patent published in 2010 - IPC A61B5/02 A61K31/44 A61K31/4155 A61P9/08 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to clinical pharmacology, and can be used for pharmacological correction of an adverse reactions on antihypertensive therapy observed in patients with bronchial asthma. That is ensured by calculation of a vegetative balance coefficient (VBC) by formula where SDNN is a standard deviation of a full RR indices array, Tp is total RR interval spectrum power. Am is mode amplitude, with SDNN_ref, Tp_ref, Am_ref indices. Before the therapy starts, SDNN_i, Tp_i, Am_i indices are calculated. If with underlying calcium antagonist pharmacotherapy, VBC>1.01 standard units is observed, sympathetic hypertonus correction is enabled by the additional introduction of the preparation Kardosten, 2 tablets twice a day combined with a calcium antagonist preparation. Calculated VBC<1.0 standard units with underlying calcium antagonist pharmacotherapy does not require vegetative imbalance correction.

EFFECT: method provides well-timed decrease of high activity of sympathetic vegetative nervous system in treating arterial hypertension in the patients with bronchial asthma.

2 ex